Biosimilars Month in Review: May 2024
The biosimilars month in review highlights recent FDA approvals and successful comparison trials.
Source: hcplive.com
Stephenb Hanauer News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Stephenb Hanauer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Stephenb Hanauer Today - Breaking & Trending Today
Infliximab Biosimilar CT-P13 Superior to Placebo for IBD Maintenance
Statistically significant higher proportions of patients with CD or UC receiving subcutaneous CT-P13 achieved clinical remission compared with placebo.
Source: hcplive.com
Biosimilars as Effective as Originator Biologics in IBD
In a systematic review, outcomes such as remission and loss of response were similar between patients with IBD who continued their original biologic and those who switched to a biosimilar.
Source: medscape.com
Data Presented at UEG Week 2023 Further Support the Potential of Celltrion's Investigational Subcutaneous Infliximab CT-P13 SC in the Treatment of Inflammatory Bowel Disease
The latest clinical trial data for subcutaneous (SC) infliximab (CT-P13 SC), presented at the United European Gastroenterology (UEG) Week 2023 in Copenhagen, further support the potential of CT-P13 SC in patients with inflammatory bowel disease (IBD).LIBERTY-CD and LIBERTY-UC are registrational studies in patients w...
Source: pharmiweb.com
Amgen, J&J settle ustekinumab patent lawsuit in potential biosimilar market shake-up
Johnson & Johnson has settled its lawsuit with Amgen regarding the latter company’s Stelara biosimilar, clearing the way for a January 2025 release date in the United States, according to results of a federal court filing. Meanwhile, the rheumatology world awaits the debut of other ustekinumab biosimilars in the market — and what they may portend for patient care moving forward
Source: healio.com